Improved detection of pre-symptomatic, non-central nervous system TDP-43 pathology in amyotrophic lateral sclerosis using RNA aptamer
Abstract
A recently developed TDP-43 RNA aptamer (TDP-43APT) with greater sensitivity and specificity for detecting pathological TDP-43, compared to currently available antibodies, has revealed novel pathologies in ALS, including early nuclear aggregation preceding disease symptoms. Moreover, whilst ALS has traditionally been considered a disease of the central nervous system (CNS), non-CNS manifestations of disease are gaining increasing awareness. Employing an antibody approach to detect pathologically phosphorylated TDP-43, we previously uncovered pre-symptomatic, systemic TDP-43 pathology in archived non-CNS tissue, taken during life. Here, using two recently developed tools, (i) TDP-43APTto identify pathological TDP-43, and (ii)in situhybridisation probes directed to a splice target of TDP-43 (Stathmin-2) to demonstrate concurrent loss of TDP-43 function, we re-examined non-CNS tissues from a variety of organ systems from this cohort ofante-mortemtissue taken from people who went on to develop ALS. Amongst non-CNS organs with evidence of pathological TDP-43 aggregation, and concurrent TDP-43 loss-of-function, occurring prior to motor symptom onset, were colon, skin, muscle, blood vessels, gallbladder, and lymph nodes. Cell types affected include sebocytes, endothelial cells, peripheral neuronal cells, dendritic cells, chondrocytes - all cells with a shared cell linage from the neural crest, implying a neurodevelopmentally-defined cell-type specific predisposition to TDP-43 pathology. This cell-type predisposition, along with TDP-43 pathology identified in tissue mobile, circulating inflammatory cells (T-cells and macrophages) may help to guide early, pre-symptomatic peripheral biopsy and biomarker development. Our findings extend the number of tissue and cell types with pathological TDP-43 aggregation outside of the CNS prior to motor symptoms, showing this is a common feature of ALS, affecting a number of organ systems that are readily accessible for biopsy. We propose that skin and gastro-intestinal tract tissues provide the most promising potential for ease of biopsy, with potential applications for ALS diagnosis and monitoring prior to motor symptom emergence amongst general and at-risk populations.
Graphical Abstract
<fig id="ufig1" position="float" orientation="portrait" fig-type="figure"><label>Graphical Abstract:</label><caption>TDP-43 RNA aptamer detects non-CNS pathological TDP-43 from ante-mortem peripheral tissues cohort taken from ALS patients prior to ALS diagnosis.
A) Cartoon depicting organs with, and without, pathological TDP-43 detected by TDP-43 RNA aptamer. B) Timeline depicting the number of years prior to motor symptom onset that pathological TDP-43 could be detected by TDP-43 RNA aptamer for lymph node, skin and gastrointestinal tract ante-mortem tissues.
</caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="648122v1_ufig1" position="float" orientation="portrait"/></fig>Related articles
Related articles are currently not available for this article.